RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.

Add to Collection
2009 Jan Others Fist_Author_Year_PM

Full Author : ['Nauck, M A', 'Ellis, G C', 'Fleck, P R', 'Wilson, C A', 'Mekki, Q']
Journal Title : International journal of clinical practice
Chapter : Section3
Journal Year : 2009
Cited by : Not Available

AIMS: To evaluate the efficacy and safety of alogliptin, a new dipeptidyl peptidase-4 inhibitor, for 26 weeks at once-daily doses of 12.5 and 25 mg in combination with metformin in patients whose HbA(1c) levels were inadequately controlled on metformin al.....

Keywords : ["multicentre randomise doubleblind placebocontrolle study", "type diabetes inadequately control", "dipeptidyl inhibitor alogliptin", "metformin therapy", "metformin monotherapy", "safety", "patient", "efficacy", "add"]